- Home
- CLYM vs SERA Comparison
CLYM vs SERA Comparison
Compare CLYM & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLYM
- SERA
- Stock Information
- Founded
- CLYM 2018
- SERA 2008
- Country
- CLYM United States
- SERA United States
- Employees
- CLYM N/A
- SERA N/A
- Industry
- CLYM
- SERA Precision Instruments
- Sector
- CLYM
- SERA Health Care
- Exchange
- CLYM NYSE
- SERA Nasdaq
- Market Cap
- CLYM 83.8M
- SERA 70.4M
- IPO Year
- CLYM 2021
- SERA 2021
- Fundamental
- Price
- CLYM $1.37
- SERA $2.77
- Analyst Decision
- CLYM Buy
- SERA
- Analyst Count
- CLYM 1
- SERA 0
- Target Price
- CLYM $10.00
- SERA N/A
- AVG Volume (30 Days)
- CLYM 389.6K
- SERA 761.7K
- Earning Date
- CLYM 08-13-2025
- SERA 08-06-2025
- Dividend Yield
- CLYM N/A
- SERA N/A
- EPS Growth
- CLYM N/A
- SERA N/A
- EPS
- CLYM N/A
- SERA N/A
- Revenue
- CLYM N/A
- SERA $115,000.00
- Revenue This Year
- CLYM N/A
- SERA $390.13
- Revenue Next Year
- CLYM N/A
- SERA $440.54
- P/E Ratio
- CLYM N/A
- SERA N/A
- Revenue Growth
- CLYM N/A
- SERA N/A
- 52 Week Low
- CLYM $1.05
- SERA $1.37
- 52 Week High
- CLYM $9.21
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- CLYM N/A
- SERA 55.77
- Support Level
- CLYM N/A
- SERA $2.34
- Resistance Level
- CLYM N/A
- SERA $2.80
- Average True Range (ATR)
- CLYM 0.00
- SERA 0.37
- MACD
- CLYM 0.00
- SERA 0.05
- Stochastic Oscillator
- CLYM 0.00
- SERA 37.00
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.